UBS Initiates Nektar Therapeutics Coverage with Neutral Rating
UBS began covering Nektar Therapeutics with a Neutral rating and set a price target of $53.00 per share.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Dow Jones Newswires, citing ratings data from Benzinga, reported that UBS initiated coverage of Nektar Therapeutics with a Neutral rating.
UBS set a price target of $53.00 per share for the company’s stock.
why it matters
The report marks UBS’s initial assessment of Nektar Therapeutics and may focus market attention on the NKTR shares, alongside the published rating and target.
instruments
sources
- Nektar Therapeutics Initiated at Neutral by UBS — Dow Jones Newswires, 12 October 2026 at 14:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗